Department of Microbiology and Immunology, Weill Cornell Medicine, New York, New York 10065, United States.
Department of Biochemistry, Weill Cornell Medicine, New York, New York 10065, United States.
J Med Chem. 2024 Apr 11;67(7):5473-5501. doi: 10.1021/acs.jmedchem.3c02097. Epub 2024 Mar 30.
Proteolysis-Targeting Chimeras (PROTACs) are bifunctional molecules that bring a target protein and an E3 ubiquitin ligase into proximity to append ubiquitin, thus directing target degradation. Although numerous PROTACs have entered clinical trials, their development remains challenging, and their large size can produce poor drug-like properties. To overcome these limitations, we have modified our Coferon platform to generate Combinatorial Ubiquitination REal-time PROteolysis (CURE-PROs). CURE-PROs are small molecule degraders designed to self-assemble through reversible bio-orthogonal linkers to form covalent heterodimers. By modifying known ligands for Cereblon, MDM2, VHL, and BRD with complementary phenylboronic acid and diol/catechol linkers, we have successfully created CURE-PROs that direct degradation of BRD4 both and . The combinatorial nature of our platform significantly reduces synthesis time and effort to identify the optimal linker length and E3 ligase partner to each target and is readily amenable to screening for new targets.
蛋白水解靶向嵌合体(PROTACs)是一种双功能分子,它能使靶蛋白和 E3 泛素连接酶接近,并附加泛素,从而引导靶蛋白降解。尽管许多 PROTACs 已进入临床试验,但它们的开发仍然具有挑战性,而且它们的体积较大可能会产生较差的类药性。为了克服这些限制,我们修改了我们的 Coferon 平台,生成了组合泛素化实时蛋白水解(CURE-PROs)。CURE-PROs 是小分子降解剂,设计通过可逆生物正交接头自组装形成共价异源二聚体。通过用互补的苯硼酸和二醇/儿茶酚接头修饰 Cereblon、MDM2、VHL 和 BRD 的已知配体,我们成功地创建了 CURE-PROs,可分别引导 BRD4 的降解。我们平台的组合性质大大减少了合成时间和工作量,可用于确定每个靶标和 E3 连接酶的最佳接头长度和组合,并易于筛选新的靶标。